Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 5, 1998, Pages 573-576

  Colzi, A ^a   Turner, K ^a   Lees, A J ^a,b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Apomorphine; Continuous drug delivery; Levodopa induced dyskinesias; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DYSKINESIA; FEMALE; HUMAN; MALE; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031923068     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.5.573     Document Type: Article

References (26)

1. Nutt JG. Levodopa-induced dyskinesias: review, observations and speculations. Neurology 1990;40:340-5.
2. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25: 523-6.
3. Lees AJ. L-dopa treatment and Parkinson's disease. Q J Med 1986;59:534-7.
4. Lang AE, Meadows JC, Parkes JD, et al. Early onset of the on-off phenomenon in children with symptomatic parkinsonism. J Neurol Neurosurg Psychiatry 1982;45:823-5.
5. Narabayashi H, Yokachi F, Nakajima Y. Levodopa-induced dyskinesias and thalamotomy. J Neurol Neurosurg Psychiatry 1994;47:831-9.
6. Dogali M, Cazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45: 753-61.
7. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1986;i:467-70.
8. Stibe CMH, Kempster PA, Lees AJ, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 988;i:403-6.
9. Sage JI, Mark MJ. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992;42(suppl 1):23-8.
10. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-6.
11. Pollak P, Champay AS, Hommel M, et al. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:544.
12. Poewe W, Kleedorfer B, Wagner M, et al. Continuous apomorphine in the treatment of Parkinson's disease. Adv Neurol 1993;60:656-9.
13. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
14. Duby SE, Cotzias GC, Papavasiliou PS, et al. Injected apomorphine and orally administered levodopa in parkinsonism. Arch Neurol 1972;27:474-80.
15. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic treatment for up to five years. Mov Disord 1993;8:165-70.
16. Cotzias GC, Mena I, Papavasiliou PS, et al. Unexpected findings with apomorphine and their possible consequences. Adv Neurol 1974;5:295-9.
17. Chaudhuri RK, Critchley P, Abbott RJ, et al. Subcutaneous apomorphine for on'off oscillations in Parkinson's disease. Lancet 1988;ii:1260.
18. Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson's disease. J Neurol 1992;239: 389-93.
19. Albin RL, Young AB, Penney JB. The functional anatomy of the basal ganglia disorders. Trends Neurosci 1989;12:366-74.
20. Herroro M, Augood SJ, Hirsch EC, et al. Effect of L-dopa on pre-proenkephalin and pre-protachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995;68:1189-98.
21. Nisbet AP, Foster OJ, Kingsbury A, et al. Pre-proenkephalin and pre-protachykinin mRNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995; 66:361-76.
22. Nisbet AP, Eve DJ, Kingsbury A, et al. Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1996;75:389-406.
23. Piccini P, Wilks RA, Burn DJ, et al. PET studies on opioid receptor binding in Parkinson's disease patients with and without levodopa-induced dyskinesias [abstract]. Neurology 1995;46(suppl 2):S6-12.
24. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45 (suppl 3):S6-12.
25. Engber TM, Suzel Z, Juncos JL, et al. Continuous and intermittent levodopa differentially affect rotation induced by D1 and D2 dopamine agonists. Eur J Pharmacol 1989;168:291-8.
26. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-3.